ABBV vs CRWD: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and CrowdStrike Holdings, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-22.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
CrowdStrike Holdings, Inc. · Technology
$449.61
+106.1% upside to fair value
Grade C
High Quality
QuantHub Verdict
CRWD has more upside to fair value
(+106.1%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
CRWD |
| Current Price |
$208.05 |
$449.61 |
| Fair Value Estimate |
$217.50 |
$926.44 |
| Upside to Fair Value |
+4.5%
|
+106.1%
|
| Market Cap |
$367.9B |
$114.0B |
| Forward P/E |
14.9x
|
-619.9x
|
| EV / EBITDA |
16.7x
|
981.7x
|
| Price / Sales |
6.1x
|
23.7x
|
| Price / FCF |
20.9x
|
92.0x
|
| Revenue Growth YoY |
+8.6%
|
+23.3%
|
| Gross Margin |
83.7%
|
74.9%
|
| Operating Margin |
34.7%
|
-5.4%
|
| Return on Equity |
-129.24%
|
-4.7%
|
| Dividend Yield |
3.2% |
0% |
| FCF Yield |
4.78%
|
1.09%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
CrowdStrike Holdings, Inc. is a leading cybersecurity company specializing in cloud-native endpoint protection and threat intelligence through its Falcon platform, which generates over 94% of its revenue from subscription services. The business quality is high due to its durable competitive moat built on cutting-edge big data security technology, strong management with a founder-led CEO who has o…
Accumulation Zones
| Metric |
ABBV |
CRWD |
| Zone Low |
$163.13 |
$694.83 |
| Zone High |
$184.88 |
$787.47 |
| In Buy Zone? |
No
|
Yes
|